NCT02925559 - Effect of Anti-diabetic Drugs on Glycemic Variability | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

January 31, 2019

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Dapagliflozin

The active treatment will include a 10 mg dose of dapagliflozin orally once a day.

DRUG

Gliclazide MR

As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.

Trial Locations (1)

Centro de Diabetes Curitiba, Curitiba